Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study [4]

Neurology

Volumn 72, Issue 16, 2009, Pages 1448-1449

  Goldstein, Larry B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; DRUG MEGADOSE; HUMAN; HYPERTENSION; LETTER; PRIORITY JOURNAL; REVASCULARIZATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; STATISTICAL SIGNIFICANCE; STROKE; TREATMENT CONTRAINDICATION; AGE; AGED; BRAIN ATHEROSCLEROSIS; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DOSE RESPONSE; EPIDEMIOLOGY; FEMALE; HYPERCHOLESTEROLEMIA; IATROGENIC DISEASE; MALE; METABOLISM; NOTE; PATHOPHYSIOLOGY; SEX DIFFERENCE; STATISTICS; CANCER MORTALITY; CORONARY ARTERY DISEASE; DRUG DOSE COMPARISON; ELDERLY CARE; HUMAN CELL; HUMAN TISSUE; LOW DRUG DOSE; MORTALITY;

AGE FACTORS; AGED; CAUSALITY; CEREBRAL HEMORRHAGE; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; IATROGENIC DISEASE; INTRACRANIAL ARTERIOSCLEROSIS; MALE; PYRROLES; SEX FACTORS;

EID: 67449132295     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000346751.39886.01     Document Type: Letter

References (8)

1. Goldstein LB, Amarenco P, Szarek M, et al, on behalf of the SPARCL Investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008;70:2364-2370.
2. O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dL: lower is better and physiologically normal. J Am Coll Cardiol 2004;43:2142-2146.
3. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvasta-tin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-559.
4. Wenger NK, Lewis SJ, Welty FK, et al, on behalf of the TNT Steering Committee and Investigators. Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. Heart 2008;94:434-439.
5. Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK, for the Treating to New Targets Study Steering Committee and Investigators. Outcomes of using high-or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 2007;147:1-9.
6. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. Stroke 2006;37:577-617.
7. Goldstein LB, Amarenco P, LaMonte M, et al. Relative effects of statin therapy on stroke and cardiovascular events in man and women. Secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study. Stroke 2008;39:2444-2448.
8. Chaturvedi S, Zivin J, Breazna A, et al. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology 2009;72:688-694.